Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.64
€0.02(0.76%)
At close: 4:00 PM EDT
€2.64
€0.02(0.76%)
Day’s Range― - ―
52-Week Range€2.32 - €3.35
Previous CloseN/A
Volume24.20K
Average Volume (3M)44.99K
Market Cap
€220.66M
Enterprise Value€291.18
Total Cash (Recent Filing)€21.58M
Total Debt (Recent Filing)€103.27M
Price to Earnings (P/E)50.0
Beta0.36
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.73%
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (Products + CDMO)A dual business model combining product commercialization and CDMO services provides structural revenue diversification. CDMO contracts can smooth utilization and bring long-term supply agreements, while product sales capture downstream margins—supporting steadier cash generation when demand normalizes.
Historically Resilient EBITDA MarginsStable EBITDA margins across 2020–2024 signal enduring operational efficiency and pricing power in key segments. This track record implies the company can generate healthy operating profitability under normal volumes, which supports durability of earnings once the 2025 disruption is addressed.
Moderate Historical Leverage And Equity GrowthA history of moderate leverage and gradual equity growth provides balance-sheet resilience and financial flexibility. This structural strength reduces bankruptcy risk, supports access to financing for capex or acquisitions, and helps absorb cyclical shocks while management stabilizes operations.
Bears Say
2025 Revenue Collapse And Margin CompressionA 20% revenue drop alongside near-zero operating margins materially weakens underlying earnings power. Such a structural hit can impair reinvestment, reduce pricing leverage, and damage market share if sustained. Recovery may take multiple quarters and could require strategic adjustments to product mix.
Weak Cash Generation & Negative Free Cash FlowSignificant negative free cash flow and collapsing operating cash restrict the firm's ability to fund capex, dividends, or working capital organically. This durable constraint increases refinancing risk and may force asset sales or higher-cost financing until cash conversion stabilizes.
Earnings Volatility And Large EPS DeclineA roughly 60% EPS decline indicates volatile profitability and weak earnings quality. Persistent earnings swings undermine strategic planning, raise the cost of capital, and make sustaining R&D or capacity investments harder, limiting long-term competitive positioning until stability returns.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.35 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €220.66M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is yesterday.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
Currently, no data Available
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 0.73%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.